Paris Margaritis: Native Cellular Biology and the Future of Durable Hemophilia A Gene Therapy
Paris Margaritis, Chief Scientific Officer at GeneVentiv Therapeutics, Inc, shared on LinkedIn about a recent article by Paige E. Severeid et al, published in Blood Advances, adding:
”A newly published study in Blood Advances provides important insight into one of the key challenges facing current FVIII gene therapies for hemophilia A.
The paper further demonstrates that endogenous FVIII is produced primarily by liver sinusoidal endothelial cells (LSECs), not hepatocytes, and highlights that ‘discordance between natural FVIII biosynthesis sites and cellular targets of adeno-associated viral vectors has been implicated in efficacy limitations of current gene therapies for HA.’
The paper further reinforces the importance of aligning gene therapy design with endogenous cellular biology, an increasingly important consideration for durable expression in hemophilia gene therapy.
This is equally interesting and important work for the field and congratulations to all the authors and Roland W Herzog and Radoslaw (Radek) Kaczmarek.
Why this is important:
This work is highly relevant for hemophilia A gene therapies given the declining or variable expression observed with hepatocyte-targeted FVIII gene therapies such as valoctocogene roxaparvovec (Roctavian).
GeneVentiv’s GENV-HEM was designed to treat hemophilia A, regardless of inhibitors, from a fundamentally different biological premise.
Rather than forcing non-native FVIII expression in hepatocytes, GENV-HEM expresses activated human Factor V (FVa) in hepatocytes, the natural cellular site for Factor V synthesis.
This native-expression approach is intended to leverage the liver’s intrinsic biology, potentially supporting improved tolerability and long-term durability, including in patients with inhibitors.
Preclinical mouse data indeed support both such durability and efficacy and clinically relevant evaluation in hemophilia A dogs is currently ongoing.”
Title: Factor VIII originates primarily from anatomically distinct subsets of liver sinusoidal endothelial cells
Authors: Paige E. Severeid, Audrey Kapelanski-Lamoureux, Cynthia Lebeaupin, Peter Metrakos, Anthoula Lazaris, Wenjun Zhang, Chandrashekhar A. Kubal, Renzhi Han, Sreevani Arisa, Oded Danziger, Brad R. Rosenberg, Eleftherios Michailidis, Charles M. Rice, Ype P. de Jong, Randal J. Kaufman, Roland W. Herzog, Radoslaw Kaczmarek
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026